Unicycive Therapeutics, Inc., (UNCY): Price and Financial Metrics
GET POWR RATINGS... FREE!
UNCY Stock Price Chart Interactive Chart >
UNCY Price/Volume Stats
| Current price | $0.85 | 52-week high | $8.73 |
| Prev. close | $0.84 | 52-week low | $0.62 |
| Day low | $0.80 | Volume | 3,500 |
| Day high | $0.90 | Avg. volume | 118,897 |
| 50-day MA | $1.03 | Dividend yield | N/A |
| 200-day MA | $1.91 | Market Cap | 12.77M |
Unicycive Therapeutics, Inc., (UNCY) Company Bio
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Latest UNCY News From Around the Web
Below are the latest news stories about Unicycive Therapeutics Inc that investors may wish to consider to help them evaluate UNCY as an investment opportunity.
Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical MeetingUnicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two abstracts supporting the potential efficacy and safety of Renazorb (lanthanum dioxycarbonate) to be presented as posters at the National Kidney Foundation (NKF) Spring Clinical Meeting taking place April 6-10, 2022 in Boston. Renazorb is a second-generation lanthanum-based phosphate binding agent utilizing proprietary nan |
Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceUnicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. |
Unicycive Therapeutics pops 6% after receiving FDA guidance on Renazorb regulatory pathwayNo summary available. |
Unicycive Therapeutics Receives FDA Guidance On Renazorb Regulatory PathwayUnicycive Therapeutics Inc (NASDAQ: UNCY ) updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate). Renazorb is a second-generation lanthanum-based phosphate-binding agent utilizing proprietary nanoparticle technology for hyperphosphatemia in patients with chronic kidney disease (CKD). In a recent Type C interaction with the FDA, Unicycive sought the FDA''s feedback on the sufficiency of the Renazorb Full story available on Benzinga.com |
Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory PathwayLOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum |
UNCY Price Returns
| 1-mo | -2.38% |
| 3-mo | -38.85% |
| 6-mo | -60.28% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -58.74% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...